ForumIAS LATEST
- 12 June | From 105 to 142 in UPSC Prelims | AIR 2 IFoS 2025 Shares His Strategy | Click Here to Watch →
- 12 June | Failed Prelims, Secured IFoS AIR 36: Nikhil's Success Story |
Click Here to Watch → - 12 June | What Helped AIR 02 Crack IFoS? SFG, Mock Tests & Answer Writing | Click Here to Watch →
News: Drugs Controller General of India(DCGI) has given approval to Serum Institute of India(SII) to conduct Phase II+III clinical trials of Oxford University AstraZeneca COVID-19 vaccine(COVISHIELD).
Facts:
- COVISHIELD: The Oxford vaccine “AZD1222” is being called Covishield in India.
- The Serum Institute of India(SII) has entered into a manufacturing partnership with biopharma major AstraZeneca to produce this Oxford vaccine.
Additional Facts:
- DCGI: It is a department of the Central Drugs Standard Control Organization(CDSCO) responsible for approval of licences of specified categories of drugs such as blood and blood products, IV fluids and vaccines in India.It comes under the Ministry of Health & Family Welfare.
- Case Fatality Rate(CFR): It is the proportion of deaths from a certain disease compared to the total number of people diagnosed with the disease for a particular period.
